Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
YieldMax MRNA Option Income Strategy ETF(MRNY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MRNY
10/23/2026: MRNY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
MRNY is an actively managed ETF that generates high monthly income by selling synthetic covered call options on Moderna (MRNA) stock. Its primary strength is providing high cash payouts, but it achieves this by sacrificing potential capital appreciation and bearing the full risk of MRNA stock volatility. It is best suited for income-focused investors looking for tactical yield, rather than those seeking long-term growth or capital preservation. The most critical risks include the concentration in a single biotech stock and potential NAV decay inherent in synthetic option strategies. Investors should monitor MRNA's volatility levels and market sentiment closely, as these determine the viability and attractiveness of the fund's income distribution.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The capped upside nature of the fund limits participation in major stock rallies. |
| Momentum investor | Strong fit while signal remains positive | The strategy may benefit from high volatility during strong uptrends, provided the call options are not tested. |
| Value investor | Weak fit | The fund is a tactical income tool rather than a vehicle for long-term fundamental value investing. |
| Dividend/Income investor | Strong fit | This fund is specifically engineered for investors prioritizing high monthly cash distributions. |
| Low-risk investor | Weak fit | High exposure to single-stock volatility makes this unsuitable for those seeking capital preservation. |
Investor Profile
Ideal Investor Profile
The ideal investor is an experienced trader or income-focused individual comfortable with high-risk, single-stock derivative strategies and short-term income generation.
Suitability
Not suitable for passive long-term investors; best for those actively managing income flow and cognizant of the risks of synthetic option structures.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | The fund is inherently tied to the high volatility of the underlying biotechnology stock. |
| Market risk | High | Significant exposure to MRNA price movements can lead to substantial capital loss. |
| Concentration | High | The fund is exclusively tied to one stock, removing any benefit of sector or issuer diversification. |
| Tracking/expense | Medium | The high expense ratio and complex derivative mechanics can create drag on total returns. |
| Liquidity | Medium | Trading costs may increase if underlying option market liquidity declines. |
| Business/sector quality | Medium / high | Biotech is a speculative sector subject to clinical trial results and regulatory developments. |
Risk Analysis
Volatility
MRNY is extremely volatile, directly linked to MRNA's stock swings and options pricing, making it a high-risk instrument.
Market Risk
The fund faces total exposure to the fortunes of Moderna; if the company underperforms, the fund's NAV may suffer significant and potentially permanent loss.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Derivatives | Moderna, Inc. (MRNA) Synthetic Covered Call Strategy | 90 | This position provides the synthetic exposure to MRNA price movements used to generate option premiums. |
| Cash/collateral | US Treasury Bills / Cash Equivalents | 10 | Collateral is held to support the options strategy and manage liquidity requirements. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type ETF | Historic Profit 37.42% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.